Skip to main content
. 2020 Apr 16;31(7-8):415–422. doi: 10.1089/hum.2019.367

Table 2.

Spread of nerve growth factor expression at the injection site

Patient Anterior Site 1: Left Anterior Site 1: Right Intermediate Site 2: Left Intermediate Site 2: Right Posterior Site 3: Left Posterior Site 3: Right
1 D/V 1.48 ± 0.37 D/V 1.04 ± 0.21 D/V 1.30 ± 0.18 D/V 0.746 D/V 1.22 ± 0.14 D/V 0.813 ± 0.13
M/L 1.59 ± 0.38 M/L 1.31 ± 0.15 M/L 1.27 ± 0.19 M/L 1.09 M/L 1.14 ± 0.19 M/L 0.467 ± 0.12
2 D/V 0.576 ± 0.26 D/V 0.878 ± 0.021 D/V 0.432 ± 0.069 D/V 0.579 D/V 0.520 ± 0.024 D/V 0.696
M/L 1.42 ± 0.054 M/L 0.460 ± 0.066 M/L 1.34 ± 0.30 M/L 0.372 M/L 0.520 ± 0.067 M/L 1.07
3 D/V 0.527 ± 0.23     D/V 1.18 ± 0.31     D/V 1.73 ± 0.47    
M/L 0.794 ± 0.22     M/L 0.712 ± 0.12     M/L 1.44 ± 0.037    

To quantify the diffusion of AAV2-NGF, the D/V and M/L spread of NGF expression (mm ± standard deviation) were measured and averaged among all sections with a detectable injection site. The mean spread of NGF expression around the injection site was 0.957 ± 0.34 mm, less than predicted by preclinical studies.

±, 1 standard deviation; AAV2, adeno-associated virus serotype 2; D/V, dorso/ventral; M/L, medio/lateral; NGF, nerve growth factor.

HHS Vulnerability Disclosure